ClinicalTrials.gg
RecruitingNCT07201129LUMIOSUpdated Jul 30, 2026

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

A Phase 3 interventional study of Cenerimod and Placebo in Nephritis, Lupus and Lupus Erythematosus, Systemic, sponsored by Viatris Innovation GmbH. Recruiting at 14 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Viatris Innovation GmbH (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.

Planned enrollment
11th of 100
300 · median 50
Started
2026
with 14 others
Phase 3
16 of 114
2 open now
Primary completion
2029-08
later than 35 of 49 live
Registered
104th of 114
by date

Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 11th largest by planned enrollment of the 100 interventional ones that give a count, is one of 15 that started in 2026, is one of 16 in phase 3, reaches primary completion later than 35 of the 49 other live ones, and was the 104th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 136 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Lupus Nephritis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod. The main questions it aims to answer are:

  • Does cenerimod improve kidney function in participants?
  • What medical problems do participants have when taking cenerimod?

Researchers will compare cenerimod to a placebo (a look-alike substance that contains no drug) to see how well cenerimod works when it is added to regular treatment.

Participants will:

  • Take cenerimod or a placebo every day for 76 weeks (approximately 1.5 years), on top of regular treatment.
  • Visit the clinic every 1 to 3 months for checkups and tests.
03

Conditions studied

  • Nephritis, Lupus
  • Lupus Erythematosus, Systemic
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Classification of systemic lupus erythematosus (SLE) made according to the 2019 European Alliance of Associations for Rheumatology / American College of Rheumatology (EULAR/ACR) criteria.
  • Renal within 6 months prior to Screening visit indicating Class III or IV active glomerulonephritis with or without co-existing Class V, OR pure Class V membranous LN. If no biopsy was performed within 6 months of Screening, a biopsy will be performed during the Screening period, after all other inclusion/exclusion criteria are verified.
  • Active renal disease defined as urine protein/creatinine ratio ≥ 1 mg/mg, assessed on a 24h urine collection.
  • ≥ 15 mL/min/1.73 m\^2. Enrollment of participants with eGFR between ≥ 15 and \< 30 mL/min/1.73 m\^2 requires:

    • a renal biopsy during the screening period showing sclerosis in ≤ 50% of glomeruli,
    • activity index ≥ 2, and chronicity index \< 4, on the National Institutes for Health 2018 activity and chronicity indices. These indices must be assessed on the kidney biopsy dated less than 6 months prior to Screening and confirmed by a nephropathologist.
  • Initiation of the induction therapy with the mandatory following background therapy:

    1. Mycophenolate mofetil 1-3 g/day orally or mycophenolate sodium 720-2160 mg/day orally at Randomization. This treatment can be in place before Screening or started at Screening.
    2. : 1-3 intravenous (i.v.) pulses of methylprednisolone at 250 to 1000 mg/pulse/day (maximum cumulative 3000 mg) followed by oral prednisone (or equivalent) at 0.5 mg/kg/day with a cap at 40 mg/day. Pulses can be administered during screening and up to 2 weeks prior to screening. Participants who cannot take the pulse i.v. corticosteroid therapy should directly start on 0.8-1.0 mg/kg/day (max 80 mg/day) oral prednisone (or equivalent), within the same window as i.v. pulses.

Note: If treatment with an antimalarial or belimumab is taken, it must be initiated at least 4 weeks prior to Screening and must be at stable dose during these 28 days prior to Randomization and continued at a stable dose until End-of-Treatment. Participants on azathioprine must be switched to mycophenolate mofetil or mycophenolate sodium prior to Randomization.

  • Participants of must agree to:

    • Use a highly effective method of from the Screening visit up to at least 24 weeks after discontinuation of trial intervention.
    • Undertake monthly urine pregnancy tests during the trial and up to at least 24 weeks after discontinuation of trial intervention.

Main Exclusion Criteria:

  • Severe active central nervous system lupus
  • History of, or current renal diseases (other than LN) that, in the opinion of the investigator, could interfere with the LN assessment and confound the disease activity assessment (e.g., diabetic nephropathy), or require dialysis, transplantation or end-stage renal disease.
  • History or presence of Mobitz type II or third-degree atrioventricular block, sick sinus syndrome, symptomatic bradycardia, or syncope associated with cardiac disorders.
  • Participants who experienced myocardial infarction, unstable angina pectoris, stroke, , vascular thrombosis, decompensated heart failure requiring hospitalization, or heart failure defined by the Class III/IV within 6 months prior to Screening.
  • Resting heart rate \< 50 bpm as measured by the 12-lead (ECG) at Screening or at Randomization.
  • Diagnosis of active or latent tuberculosis at Screening or within 6 months prior to Screening
  • Negative antibody test for varicella-zoster virus
  • Positive results for serological markers for hepatitis A, B, C and E indicating acute or chronic infection
  • Participants with a positive (HIV) test or who have any other congenital or acquired immunodeficiency
  • Presence of any of the following abnormalities, detected during the ophthalmological evaluation and/or by optical coherence tomography, as evaluated by the site ophthalmologist, during Screening:

    • Macular edema of any cause: diabetic, cystoid, tractional.
    • Foveal degeneration: macular hole, macular pseudohole, hereditary or degenerative maculopathies.
    • Active uveitis, papilledema.
    • Retinal neovascularization of any cause and in any location.
  • Significant hematology abnormality at Screening:

    • \< 7 g/dL;
    • Lymphocyte count \< 500 /μL (0.5 × 10\^9/L);
    • White blood cell count \< 1500/μL (1.5 × 10\^9/L) or
    • \< 25,000/μL (25 × 10\^9/L)
  • Treatment with the following medications within 5 half-lives of the medication prior to Randomization: Cyclosporine, voclosporin, tacrolimus, sirolimus, cyclophosphamide.
  • Treatment with the following medications within 90 days prior to Randomization:

    • Leflunomide.
    • i.v. immunoglobulins.
    • Methotrexate.
    • Tyrosine kinase inhibitors.
  • Treatment with anifrolumab within 6 months prior to Randomization.
  • Treatment with biological agents, (e.g., anti-tumor necrosis factor [anti-TNF], anti-interleukin-1 [anti-IL1], anti-IL6 therapies) within 90 days prior to Randomization.
  • Treatment with B cell-depleting biological agents (e.g., rituximab, obinutuzumab or ocrelizumab) within 12 months prior to Randomization.
  • Treatment with any of the following medications any time prior to Screening:

    • Alemtuzumab.
    • Sphingosine-1-phosphate receptor modulators (e.g., fingolimod).
    • Participants previously randomized to cenerimod or placebo in any trial involving cenerimod.
  • Pregnancy confirmed via a serum pregnancy test at the Screening visit or a urine/serum pregnancy test at the Randomization visit or planning to become pregnant, or lactating participant.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Cenerimod 4 mg

    Participants will receive cenerimod once daily in addition to background lupus nephritis (LN) therapy.

    Drug: Cenerimod

  • Placebo comparator
    Matching placebo

    Participants will receive matching placebo once daily in addition to background LN therapy.

    Drug: Placebo

Interventions

  • Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg.

    Also known as: ACT-334441

  • DrugPlacebo

    Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.

06

What researchers measure

Primary outcomes

  1. Complete renal response (CRR)

    CRR at Week 76, defined as (both must be met): * Urine protein to creatinine ratio (UPCR) ≤ 0.5 mg/mg AND * No decrease from baseline of ≥ 20% in estimated glomerular filtration rate (eGFR)

    Time frame: At Week 76

Secondary outcomes

  1. CRR while maintaining a low dose of corticosteroids

    CRR at Week 76 with oral daily dose of 5 mg/day prednisone equivalent or less from Week 24 onwards

    Time frame: At Week 76

  2. Sustained CRR

    Sustained CRR at Week 76. Sustained CRR is defined as meeting CRR criteria for two consecutive visits (i.e., 3 months apart) and confirmed at Week 76 visit. The second consecutive visit can be the Week 76 visit to qualify as sustained CRR.

    Time frame: Up to Week 76

07

Study locations

14 of 14 sites recruiting
  • Dolphin Medical Research
    Doral, Florida 33172, United States
    Recruiting
  • Alloy Clinical Research LLC
    Kissimmee, Florida 34741, United States
    Recruiting
  • SouthCoast Research Center
    Miami, Florida 33136, United States
    Recruiting
  • Allied Biomedical Research Institute
    Miami, Florida 33155, United States
    Recruiting
  • DH NationalResearchCenters INC
    Miami, Florida 33155, United States
    Recruiting
  • ProfessionalResearchCenter INC
    Miami, Florida 33172, United States
    Recruiting
  • San Marcus Research Clinic, Inc.
    Miami Lakes, Florida 33014, United States
    Recruiting
  • Revive Research Institute, LLC
    Sterling Heights, Michigan 48313, United States
    Recruiting
  • Rheumatology Care Center, PLLC
    Bellaire, Texas 77401, United States
    Recruiting
  • Texas Arthritis Center
    El Paso, Texas 79902, United States
    Recruiting
  • Novel Research, LLC.
    Houston, Texas 77024, United States
    Recruiting
  • Northwest Houston Arthritis
    Houston, Texas 77090, United States
    Recruiting
  • Discovery Clinical Trials LLC
    San Antonio, Texas 78229, United States
    Recruiting
  • Azul Bioresearch Llc
    Sugarland, Texas 77479, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Aug 2029, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2025
First posted
Oct 1, 2025
StartActual
Feb 9, 2026
Primary completionEst.
Aug 2029
CompletionEst.
Feb 2030
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07201129
Responsible party
Sponsor
First posted
Oct 1, 2025
Start date
Feb 9, 2026
Primary completion
Aug 2029 (estimated)
Completion
Feb 2030 (estimated)
Last update
Jul 30, 2026

Study contacts

Viatris Innovation Clinical Trial Information
Contact
viatrisinnovationclinicaltrials@viatris.com
+1 833 643 8188
Clinical Trials
study director · Viatris Innovation GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cenerimod

Start the discussion